Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gottlieb, S.
Right arrow Articles by Haywood, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gottlieb, S.
Right arrow Articles by Haywood, L.

Chest, Vol 78, 880-882, Copyright © 1980 by American College of Chest Physicians

ARTICLES

Late, late doxorubicin cardiotoxicity

SL Gottlieb, WA Edmiston Jr and LJ Haywood

Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent. Cardiomyopathy is frequent when the total dose exceeds 600 mg/m2 and occurs within one to six months after cessation of therapy. A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.


This article has been cited by other articles:


Home page
 JCOHome page
J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by the American College of Chest Physicians.